MarketPulse
C

$CPRX

4 articles found
3 positive
0 negative
1 neutral
BenzingaBenzinga··Vandana Singh

Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1B in Rare Disease Push

Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion at $31.50 per share, with concurrent patent litigation resolution for rare disease drug Firdapse.
CPRXacquisitionM&A
GlobeNewswire Inc.GlobeNewswire Inc.··Catalyst Pharmaceuticals, Inc.

Catalyst Pharma Secures Patent Protection for FIRDAPSE Through 2035 Settlement

Catalyst Pharma settles patent litigation with Hetero Labs, blocking generic FIRDAPSE entry until 2035. Fourth major competitor settlement extends exclusivity.
CPRXrare diseasepatent settlement
BenzingaBenzinga··Globe Newswire

Angelini Pharma Acquires Catalyst for $4.1B, Marking Bold U.S. Market Entry

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion in all-cash deal, marking entry into U.S. market and strengthening rare disease focus.
CPRXacquisitionM&A
Investing.comInvesting.com··Gurufocus

Catalyst Pharmaceuticals Trades at Deep Discount Despite Strong Cash Generation

Catalyst Pharmaceuticals trades at 20-33% discount to peers with 7.5% FCF yield; 2026 Hetero litigation is binary catalyst determining if shares reach $28-32 or collapse to $16-20.
CPRXpatent cliffvaluation discount